Bionomics to Showcase Innovations at Maxim Healthcare Summit
ADELAIDE, Australia and CAMBRIDGE, Mass. — Bionomics Limited (Nasdaq: BNOX), a prominent clinical-stage biotechnology company, is eager to share its groundbreaking efforts in developing novel treatments for serious central nervous system (CNS) disorders. With a focus on high unmet medical needs, Bionomics has been invited to participate in the upcoming 2024 Maxim Healthcare Virtual Summit, hosted by Maxim Group LLC. This exciting event kicks off on October 15, 2024, at 9:00 a.m. E.T.
CEO Spyros Papapetropoulos to Lead Discussion
During the summit, Bionomics' President and CEO, Spyros Papapetropoulos, M.D., Ph.D., is set to engage in a fireside chat with Senior Analysts from Maxim Group. This interactive session is scheduled for October 16 at 10:30 a.m. E.T., providing a unique opportunity for attendees to learn more about Bionomics' innovative approaches to CNS disorders.
How to Attend the Summit
Those interested in attending the summit can easily sign up to become an M-Vest member, which will grant access to the event and further updates on Bionomics' advancements. This initiative reflects the company's commitment to transparency and engagement with stakeholders.
Meet the Team Behind Bionomics
For any inquiries related to Bionomics, individuals can reach out to key contacts within the company. Rajeev Chandra, Company Secretary, is available for general queries via email. Additionally, Investor Relations representatives Kevin Gardner and Chris Calabrese are on hand for inquiries about the company's financial and operational updates.
Understanding Bionomics' Mission
Bionomics is on a mission to pioneer innovative treatments for patients grappling with serious CNS conditions. Their lead drug candidate, BNC210, is on the frontline in the battle against social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD). This proprietary, selective negative allosteric modulator of the ?7 nicotinic acetylcholine receptor represents a promising breakthrough for effective treatment.
Collaborative Efforts with Merck & Co.
Further fortifying its research and development, Bionomics has entered a strategic partnership with Merck & Co., Inc. (known as MSD in markets outside the United States and Canada). Together, they are advancing two drugs currently in early-stage clinical trials aimed at addressing cognitive deficits prevalent in Alzheimer's disease and other CNS complications.
Expanding the Pipeline
In addition to BNC210, Bionomics' robust pipeline features preclinical assets targeting Kv3.1/3.2 and Nav1.7/1.8 ion channels. These efforts are geared towards delivering solutions for CNS conditions that present significant challenges to patients and the healthcare community.
About Maxim Group LLC
Maxim Group LLC is a well-respected, full-service investment banking and wealth management firm based in New York. Known for offering a comprehensive suite of financial services—including investment banking, private wealth management, and institutional equity—Maxim Group is a registered broker-dealer and actively contributes to the financial landscape.
Connecting with Bionomics
Bionomics is not only focused on its current innovations but is also committed to collaborating with broader healthcare initiatives. By staying engaged with its audience through events like the Maxim Healthcare Summit, Bionomics highlights its dedication to advancing and supporting better healthcare solutions worldwide.
Frequently Asked Questions
What is the Maxim Healthcare Summit?
The Maxim Healthcare Summit is an annual event that brings together healthcare leaders to discuss innovations and advancements in the field.
Who is presenting at the summit on behalf of Bionomics?
Spyros Papapetropoulos, M.D., Ph.D., the President and CEO of Bionomics, will present and participate in discussions.
What is BNC210?
BNC210 is Bionomics' lead drug candidate aimed at treating social anxiety disorder and PTSD through innovative mechanisms.
What partnership does Bionomics have in its research?
Bionomics has a strategic partnership with Merck & Co., focusing on developing therapies for cognitive deficits related to Alzheimer's and other CNS disorders.
How can I contact Bionomics for more information?
You can reach out to Rajeev Chandra for general inquiries or contact the Investor Relations team for investment-related questions.
